<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210216050379N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-15</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of New oxygenation device on respiratory function enhancment.</public_title>
      <acronym></acronym>
      <scientific_title>The prevention effect of new oxygenation device versus nasal cannula in increasing exhalation co2</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>200</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63114</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Other design features: The device was tested by studying cataract patients and had significant results and was accepted at the World Anesthesia Congress in Prague, Randomization description: 200 patients scheduled for blepharoplasty  surgery by simple randomization located in two groups:nasal canulla and new oxygenation device .the method of randomization and concealment was as follows:we started from the number1 to 200 and assigned the odd numbers to the nasal canulla group and the even numbers to the new ventilation device, Blinding description: The researcher and the person conducting the measurement and data collection do not know the patient grouping.</study_design>
      <phase>N/A</phase>
      <hc_freetext>The preventive effect of new oxygenation device versus nasal canulla in increasing exhalation Co2.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in intervention group (A) receive 4 liters per minute of oxygen by a new oxygenation device that is sterile, reusable and washable. The polylactic acid weighs 110 grams and then placed on the patient's chest and with complete cardio-respiratory monitoring (EKG, SPO2, End Tidal co2, BP, RR)  the patient's hemodynamic status and with the Richmond questionnaire, sedation status of The onset of the operation is measured and recorded up to 10 minutes after the operation, then the results are given to a statistician to analyze the data are obtained. P-value less than 0.05 will be considered significant. Intervention 2: Control group: Patients in this group (B) are traditionally treated using a disposable nasal cannula made by Supao Company with a flow of 4 liters per minute of oxygen.Capnotrack is attached to the nasal cannula and exhaled carbon dioxide is transferred to the capnograph, and as intervention  group, complete cardio respiratory monitoring is performed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual data is shared after it is unidentifiable and the main outcome

When:
From May 1402 onwards

To whom:
Professors and Medical students

Conditions:
For more research

Where to obtain:
Contact Hamidreza Azizifarsani by email

How to obtain:
up to 10 days after the call

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamidreza Azizifarsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>NO.1,Shahid lamee st,faraze jonobi,koye faraz,saadatabad,Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1981956316</zip>
        <telephone>+98 21 2238 2080</telephone>
        <email>h.faresani@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamidreza Azizifarsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 1, Shahid lamee st, faraze jonobi, koye faraz, saadat abad,Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1981956316</zip>
        <telephone>+98 21 2238 2080</telephone>
        <email>h.faresan@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Local blepharoplasty surgery via intravenous sedation</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Chronic pulmonary, cardiovascular, renal, hepatic dysfunction or psychiatric disorders.
Sever chest wall deformity.
Patients without the possibility of cooperation such as language problems or deafness.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>موضوع ما بیماری نیست</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in intervention group (A) receive 4 liters per minute of oxygen by a new oxygenation device that is sterile, reusable and washable. The polylactic acid weighs 110 grams and then placed on the patient's chest and with complete cardio-respiratory monitoring (EKG, SPO2, End Tidal co2, BP, RR)  the patient's hemodynamic status and with the Richmond questionnaire, sedation status of The onset of the operation is measured and recorded up to 10 minutes after the operation, then the results are given to a statistician to analyze the data are obtained. P-value less than 0.05 will be considered significant.</i_keyword>
      <i_keyword>Control group: Patients in this group (B) are traditionally treated using a disposable nasal cannula made by Supao Company with a flow of 4 liters per minute of oxygen.Capnotrack is attached to the nasal cannula and exhaled carbon dioxide is transferred to the capnograph, and as intervention  group, complete cardio respiratory monitoring is performed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Measurement of End tidal co2 and peripheral oxygen saturation. Timepoint: IN 0, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 minutes. Method of measurement: Capnography and Pulse oximetery device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Respiratory Rate. Timepoint: In 0, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80 and 90 minutes. Method of measurement: Inspection ,counting the number of inhales and exhales in the mentioned minutes.</sec_outcome>
      <sec_outcome>Blood pressure. Timepoint: In 0, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 minutes. Method of measurement: Sphygmomanometer (non invasive).</sec_outcome>
      <sec_outcome>Agitation and restlessness. Timepoint: In 0, 5, 10,15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 minutes. Method of measurement: Richmond Agitation -sedation Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-10</approval_date>
        <contact_name>Ethics committee of shahid beheshti university of medical science</contact_name>
        <contact_address>Medical school, Shahid Beheshti University of Medical Sciences, Arabi Ave, Daneshjoo Blvd, Velengak, Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
